NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $19.89.

NEO has been the subject of several research analyst reports. Benchmark restated a "buy" rating and issued a $18.00 target price on shares of NeoGenomics in a report on Tuesday, September 24th. Stephens reaffirmed an "overweight" rating and set a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday, September 25th.

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC acquired a new stake in shares of NeoGenomics during the third quarter valued at $1,101,000. Fernwood Investment Management LLC boosted its position in NeoGenomics by 1.0% during the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company's stock worth $1,320,000 after acquiring an additional 900 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in NeoGenomics by 5.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 45,104 shares of the medical research company's stock worth $665,000 after acquiring an additional 2,166 shares during the period. Blue Trust Inc. grew its stake in NeoGenomics by 42.3% in the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company's stock worth $46,000 after acquiring an additional 987 shares during the period. Finally, Creative Planning lifted its stake in shares of NeoGenomics by 42.3% during the 3rd quarter. Creative Planning now owns 23,547 shares of the medical research company's stock worth $347,000 after purchasing an additional 7,004 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.

NeoGenomics Stock Performance

Shares of NASDAQ NEO traded up $0.79 during midday trading on Tuesday, hitting $14.93. 1,572,860 shares of the company's stock were exchanged, compared to its average volume of 815,869. The firm's fifty day simple moving average is $14.75 and its 200-day simple moving average is $14.71. NeoGenomics has a twelve month low of $12.77 and a twelve month high of $21.22. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.